Dr Bizzari holds a medical degree from the University of Nice (France) and trained as an oncologist at the Pitie Salpetriere hospital in Paris.
He continued his training in Toronto (Ontario Cancer Institute – Canada) and Montreal (Mac Gill Cancer Center – Canada) before joining the pharmaceutical industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France). In 1993, he joined Rhone-Poulenc Rorer as Vice President of Clinical Oncology, based in Paris and subsequently moved to Collegeville (PA – USA) in 1997. With the merger of Rhone-Poulenc Rorer with HMR (to form Aventis), he was responsible for the Oncology Clinical Development at Aventis as Vice President. From April 2002 until September 2008, he was the Vice President of Clinical Development, Oncology, of sanofi-aventis in Malvern, PA. Dr. Bizzari joined Celgene in October 2008 as Senior Vice President, Clinical Development Oncology. He was the Executive Vice President of Clinical Development in Celgene and was responsible for the development of Revlimid, Vidaza, Pomalidomide and Abraxane. Some of Dr. Bizzari’s past accomplishments include, the Clinical Development of several anti-cancer agents such as: Fotemustine, Taxotere, Irinotecan, Gliadel and Eloxatin. Dr. Bizzari has also been involved in the development of numerous cytostatics compounds such as anti-angiogenics (VEGF-trap), gene therapy, vaccines and bio-reductive agents. He has published more than 70 articles in peer review journals and more than 160 abstracts in scientific congresses.
Dr. Bizzari’s research interests include the methodology of clinical trials, clinical development of non-cytotoxic agents and PK/PD analysis.